The **GALACTIC-HF** study assessed the efficacy and safety of the cardiac myosin activator, omecamtiv mecarbil, in HFrEF patients, enrolling patients in both the inpatient and outpatient settings. The primary endpoint of a first HF event or CV death was reduced by 8%. There was no significant reduction in CV mortality. Currently, this drug is not licensed for use in HF. However, in the future it may be able to be considered, in addition to standard therapy for HFrEF to reduce the risk of CV mortality and hospitalization for HF

[2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | European Heart Journal | Oxford Academic (mcmaster.ca)](https://academic-oup-com.libaccess.lib.mcmaster.ca/eurheartj/advance-article/doi/10.1093/eurheartj/ehab368/6358045?s=09#298271486)